- Home
- TPST vs HCWB Comparison
TPST vs HCWB Comparison
Compare TPST & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | HCWB |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 5.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TPST | HCWB |
|---|---|---|
| Price | $3.11 | $1.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $12.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 190.6K | 49.4K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $422,026.00 |
| Revenue This Year | N/A | $178.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.87 | $1.52 |
| 52 Week High | $13.65 | $41.20 |
Technical Indicators
Market Signals| Indicator | TPST | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 27.48 |
| Support Level | $2.87 | $1.52 |
| Resistance Level | $3.23 | $2.15 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | 0.23 | 0.02 |
| Stochastic Oscillator | 39.75 | 2.22 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.